Leah Rush's Stock Ratings

Overall Average Return

23.5%

Smart Score

Overall Average Return Percentile

80th

Number of Ratings

2

		Buy Now								Get Alert
12/23/2024	EXEL	Buy Now	Exelixis	$41.15	—	Leah Rush65%	—	Initiates	→ Buy	Get Alert
11/13/2024	SYRS	Buy Now	Syros Pharmaceuticals	$0.00	—	Leah Rush65%	—	Downgrade	Buy → Hold	Get Alert

Recent Analyst Stock Rating News

From Slaughter To Sativa: Livestock Farmers Are Switching To Cannabis

From Slaughter To Sativa: Livestock Farmers Are Switching To Cannabis

This article was originally published on The Fresh Toast and appears here with permission.

Black Veteran Sent To Prison For Medical Marijuana: What's Wrong With Our Cannabis Laws?

Black Veteran Sent To Prison For Medical Marijuana: What's Wrong With Our Cannabis Laws?

By Leah Nelson, Research Director at Alabama Apppleseed Center for Law and Justice. PICKENS COUNTY — Sean and Eboni Worsley’s nightmare began with music a police officer found too loud for his liking.

BMO, Oppenheimer Out Bullish On Constellation Pharma's Cancer Treatment Opportunity

BMO, Oppenheimer Out Bullish On Constellation Pharma's Cancer Treatment Opportunity

Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst

Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst

5 Keys To Understanding Syros Pharma's ASH Presentation

5 Keys To Understanding Syros Pharma's ASH Presentation

Upside And Downside Scenarios For Celgene; Is The Selloff Overdone?

Upside And Downside Scenarios For Celgene; Is The Selloff Overdone?

Oppenheimer Bullish On Entire Biotech Sector

Oppenheimer Bullish On Entire Biotech Sector

Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch

Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch

Amgen Shares Are Nearing A Unique Inflection Point

Amgen Shares Are Nearing A Unique Inflection Point

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook